Navigation Links
Nautilus Neurosciences Announces New Patent Issued
Date:2/1/2012

BEDMINSTER, N.J., Feb. 1, 2012 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that United States Patent and Trademark Office has issued U.S. Patent 8,097,651 entitled "Diclofenac formulations and methods of use." This patent relates to methods and formulations for treating migraine. Additionally, methods are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. The patent provides additional protection for Cambia™, Nautilus' marketed product for the treatment of migraine through June 2026. This patent was licensed to Nautilus for Cambia™ in the North American markets by the Swiss company APR Applied Pharma Research, and is now listed in the FDA's Orange Book.

This coverage is in addition to that provided by U.S. Patent Nos. 7,759,394; 7,482,377; and 6,974,595.

About CAMBIA™

Nautilus' lead product, CAMBIA™, is a novel treatment for acute migraine in adults. CAMBIA is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using Dynamic Buffering Technology (DBT), CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. Designed to treat the underlying pathophysiology of migraine, Cambia reaches peak blood levels within 15 minutes and has been proven to provide equally as rapid relief in migraine. The FDA approval of CAMBIA was based on two Phase 3 placebo-controlled trials showing that CAMBIA was superior to placebo in all four FDA-mandated co-primary end points for migraine -- pain, nausea, photophobia and phonophobia. Both studies also showed that reduction in pain intensity was significantly greater in the CAMBIA group than in the placebo group as early as 15 minutes following treatment, and headache response rates were superi
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
4. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
5. Intellect Neurosciences, Inc. to Present at OneMedForum
6. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
7. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
8. Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimers Disease and Other Proteinopathies
9. Intellect Neurosciences Issues Letter to Shareholders
10. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
11. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... SAN DIEGO , Oct. 21, 2014 /PRNewswire/ ... announced today the latest genomics research centers to ... the Salk Institute, the National Cancer Institute (NCI), ... National Sequencing Center). Before Irys, obtaining a comprehensive ... because next generation sequencing (NGS) does not deliver ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... Inc. announced today that it has raised $19.2 million ... GBS Venture Partners and BioPacificVentures participated in the round. ... from additional investors in a second closing, scheduled for ... us to take essential steps for the development of ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... into a multi-year research collaboration agreement through the Stanford ... collaborative and innovative research projects in the early phases ... Dr. Paul Chew, Senior Vice President, U.S. Chief Science ...
Cached Medicine Technology:CoDa Therapeutics Closes $19 Million Series B Financing Round 2CoDa Therapeutics Closes $19 Million Series B Financing Round 3CoDa Therapeutics Closes $19 Million Series B Financing Round 4Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 2Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 3
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... The U.S. Pharmacopeial (USP) Convention is pleased ... from the Cooperation on International Traceability in Analytical ... on Metrology in Chemistry in 2008. , USP,s ... Reference Standards Program: Certified Reference Materials," was published ...
... NovoCure Ltd. presented results yesterday evaluating the Novo-TTF ... trial that showed the device enhanced the efficacy ... multiforme (GBM) patients. When used in combination with ... that uses low intensity alternating electric fields to ...
... QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; ... will host a webcast presentation on Tuesday, December 16, ... senior management team will discuss the product profile, clinical ... novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist ...
... 24 Availity, L.L.C. was,recognized as the ... Site in the,Business/Process Improvement Applications or Products ... Conference November 11 in Orlando, Florida. The,eHealthcare ... & Trends,a leading internet publication and online ...
... new treatments, researchers say , , MONDAY, Nov. 24 (HealthDay News) ... system and blood vessels may contribute to epileptic seizures, new ... case, such interactions may be a target for new treatments ... the Nov. 23 issue of Nature Medicine . , ...
... 24 Aurora Health Care Ventures has been,granted ... Inc. for Aurora Pharmacy and a health-oriented retail ... The accreditation applies to Aurora,s 130 retail pharmacies, ... retail store inside Aurora,St. Luke,s Medical Center in ...
Cached Medicine News:Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 2Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 3Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 4Health News:Availity Achieves 2008 eHealthcare Leadership Award 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Accreditation Commission for Health Care Accredits Aurora Pharmacy Sites, Retail Store 2
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: